RxDoctor Payments Data

Rishi Basnyat, MD

Internal Medicine · Phoenix, AZNPI 1609158799

Payments from drug & device makers

$1,531in general payments, 2019–2025

Across 23 payments — averaging $66.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$314
  • Corcept Therapeutics$185
  • Abbott$160
  • Inspire Medical Systems, Inc.$158
  • Mallinckrodt Hospital Products Inc.$145
  • Gilead$125
  • plus $444 from 8 others

What the payments were for

  • Food & beverage$1,527100%
  • Education$40%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,531 in reported general payments places this provider in the 80th percentile of 2,212 internal medicine providers in Arizona.

See all internal medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$28,341
Medicare patients
135
Services billed
271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide181$226,149
MounjaroTirzepatide48$56,573
EliquisApixaban18$17,649
JardianceEmpagliflozin14$16,856
FarxigaDapagliflozin Propanediol12$13,109
Breo ElliptaFluticasone/Vilanterol14$9,232
LinzessLinaclotide13$6,838
Omeprazole119$2,537
Rosuvastatin Calcium159$2,385
Levothyroxine Sodium216$2,296
Atorvastatin Calcium196$2,055
Albuterol Sulfate HfaAlbuterol Sulfate59$1,542
Losartan Potassium149$1,502
Ezetimibe35$1,392
Diclofenac Sodium33$1,315

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$314$226,149181 claims
Lilly USA, LLCMounjaro$121$56,57348 claims
AbbVieLinzess, Synthroid$14$7,79426 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,212 internal medicine providers in Arizona.

Other internal medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →